NXTC Q4 2019 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$35M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$9M-468.4% margin

Operating Income

-$12M-599.0% margin

Net Income

-$11M-545.0% margin

EPS (Diluted)

$-4.77

QoQ Revenue Growth

+26.7%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$567,000

Balance Sheet

Total Assets

$356M

Total Liabilities

$35M

Stockholders' Equity

$321M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$9M	-$6M	-48.8%
Operating Income	-$12M	-$7M	-69.9%
Net Income	-$11M	-$7M	-59.2%